Wnt/Β-Catenin activation promotes prostate tumor progression in a mouse model

Oncogene

Volumn 30, Issue 16, 2011, Pages 1868-1879

  Yu, X ^a   Wang, Y ^b   Degraff, D J ^a   Wills, M L ^a   Matusik, R J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Advanced Biotechnologies Inc   (United States)

Author keywords

AR; Foxa2; prostate; T antigen; Wnt catenin

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; HEPATOCYTE NUCLEAR FACTOR 3BETA; MATRILYSIN; VIRUS LARGE T ANTIGEN; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION;

ADENOCARCINOMA; ANIMALS; BETA CATENIN; DISEASE PROGRESSION; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; WNT PROTEINS;

MUS;

EID: 79955479314     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.560     Document Type: Article

References (44)

1. Barth AI, Stewart DB, Nelson WJ. (1999). T cell factor-activated transcription is not sufficient to induce anchorage-independent growth of epithelial cells expressing mutant beta-catenin. Proc Natl Acad Sci USA 96: 4947-4952. (Pubitemid 29214516)
2. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P et al. (1999). Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13: 966-977. (Pubitemid 29200980)
3. Bonfil RD, Chinni S, Fridman R, Kim HR, Cher ML. (2007). Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis. Urol Oncol 25: 407-411. (Pubitemid 47362762)
4. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A et al. (2005). Invasion and metastasis in colorectal cancer: epithelial- mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 179: 56-65. (Pubitemid 40976289)
5. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA et al. (2001). Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98: 10356-10361. (Pubitemid 32803024)
6. Bruxvoort KJ, Charbonneau HM, Giambernardi TA, Goolsby JC, Qian CN, Zylstra CR et al. (2007). Inactivation of apc in the mouse prostate causes prostate carcinoma. Cancer Res 67: 2490-2496. (Pubitemid 46548933)
7. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510. (Pubitemid 41746348)
8. Chesire DR, Ewing CM, Gage WR, Isaacs WB. (2002). In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21: 2679-2694. (Pubitemid 34478326)
9. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. (2000). Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 45: 323-334.
10. Crawford HC, Fingleton B, Gustavson MD, Kurpios N, Wagenaar RA, Hassell JA et al. (2001). The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 21: 1370-1383. (Pubitemid 32114984)
11. de la TA, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M et al. (2003). Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 9: 1801-1807. (Pubitemid 36554607)
12. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C et al. (2007). Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 67: 8065-8080. (Pubitemid 47395141)
13. Fingleton B. (2006). Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11: 479-491. (Pubitemid 43258157)
14. Gupta A, Wang Y-Q, Browne C, Kim S, Case TC, Paul M et al. (2008). Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate 68: 50-60.
15. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M et al. (1999). Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 18: 5931-5942. (Pubitemid 29515670)
16. Huang D, Du X. (2008). Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol 14: 1823-1827. (Pubitemid 351523810)
17. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA et al. (2007). Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 9: 938-950. (Pubitemid 350086439)
18. Kasper S. (2005). Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 94: 279-297. (Pubitemid 41420307)
19. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS et al. (1998). Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 78: 319-334.
20. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM et al. (2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99: 2884-2889. (Pubitemid 34240555)
21. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. (2004). Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6: 185-195. (Pubitemid 39485690)
22. Lamberti C, Lin KM, Yamamoto Y, Verma U, Verma IM, Byers S et al. (2001). Regulation of beta-catenin function by the IkappaB kinases. J Biol Chem 276: 42276-42286.
23. Levine AJ, Momand J. (1990). Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta 1032: 119-136.
24. Masumori N, Thomas TZ, Case T, Paul M, Kasper S, Chaurand P et al. (2001). A probasin-large T antigen transgenic mouse line develops prostate adeno and neuroendocrine carcinoma with metastatic potential. Cancer Res 61: 2239-2249. (Pubitemid 32692054)
25. Miller JR. (2002). The Wnts. Genome Biol 3: 1-15.
26. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. (2006). Expression and role of Foxa proteins in prostate cancer. Prostate 66: 1013-1029.
27. Mirosevich J, Gao N, Matusik RJ. (2005). Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate 62: 339-352. (Pubitemid 40224139)
28. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S. (2001). Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 153: 1161-1174.
29. Polakis P. (2000). Wnt signaling and cancer. Genes Dev 14: 1837-1851. (Pubitemid 30639518)
30. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R et al. (2010). Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendo-crine prostate tumors. Cancer Cell 18: 23-38.
31. Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S et al. (2003). Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int 91: 438-445. (Pubitemid 36359624)
32. Song Z, Wu X, Powell WC, Cardiff RD, Cohen MB, Tin RT et al. (2002). FGF8, Isoform b overexpression in prostate epithelium: A new mouse model for prostatic intraepithelial neoplasia. Cancer Res 62: 5096-5105. (Pubitemid 34984439)
33. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R. (2006). Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 99: 402-410. (Pubitemid 44435558)
34. Wang W, Epstein JI. (2008). Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 32: 65-71.
35. Wang Y-Q, Kasper S, Yuan J, Jin RJ, Zhang J, Ishii K et al. (2006). Androgen dependent prostatic epithelial cell selection by targeting ARR2PBNeo to the LPB-Tag transgenic model of prostate cancer. Lab Invest 86: 1074-1088. (Pubitemid 44423071)
36. Wilson CL, Matrisian LM. (1996). Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 28: 123-136. (Pubitemid 26072499)
37. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M et al. (2003). WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201: 204-212. (Pubitemid 37258931)
38. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ et al. (2001). Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101: 61-69. (Pubitemid 32186310)
39. Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL et al. (2005). A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res 65: 5263-5271. (Pubitemid 40827337)
40. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S et al. (2006). Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 30: 705-712. (Pubitemid 44264995)
41. Yardy GW, Brewster SF. (2005). Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 8: 119-126. (Pubitemid 43118074)
42. Yu X, Gupta A, Wang Y-Q, Suzuki K, Mirosevich J, Orgebin-Crist MC et al. (2005). Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann N Y Acad Sci 1061: 77-93. (Pubitemid 43211588)
43. Yu X, Wang Y-Q, Jiang M, Bierie BB, Hayward SW, Shen MM et al. (2009). Activated beta-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 69: 249-262.
44. Zhang X, Chen MW, Ng A, Ng PY, Lee C, Rubin M et al. (1997). Abnormal Prostate Development in C3(1)-bcl-2 Transgenic Mice. Prostate 32: 16-26. (Pubitemid 27274356)